Wed, May 14, 8:02 PM (35 days ago)
**Monogram Technologies Inc. (MGRM) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No product sales reported for Q1 2025. - **Profit Margins:** Operating loss of $3.3 million, slightly improved from $3.6 million in Q1 2024. - **Cash Flow:** Negative cash flow from operations at $2.3 million, an improvement from $3.6 million in Q1 2024. - **Earnings Changes:** Net loss of $3.2 million, a slight improvement from $3.5 million in Q1 2024. - **Cash Position:** $13.3 million in cash as of March 31, 2025, down from $15.7 million at the end of 2024. **Quarterly Performance Discussion:** - **Operating Expenses:** Decreased by 8% YoY, with R&D expenses down 6%, marketing expenses down 63%, and general admin expenses down 5%. - **Other Income:** Interest income increased by $43,000. - **Capital Raising:** Raised $82,000 from warrant exercises and has access to additional capital through existing agreements. **Trends and Uncertainties:** - **Regulatory Milestones:** FDA clearance for the Monogram mBôs™ TKA System in March 2025. - **Market Risks:** Tariffs and geopolitical tensions could impact future operations and supply chains. - **Legal and Regulatory:** Potential litigation with Mount Sinai over a licensing agreement. - **Operational Risks:** Proposed Texas legislation could limit access to cadaveric specimens, affecting testing and marketing efforts. **Future Operations Impact:** - **Commercialization:** Plans to integrate system upgrades and begin market adoption. - **Clinical Trials:** Initiating a 102-patient clinical trial in India. - **Funding:** Continued reliance on equity offerings and debt financings to meet capital needs. **Summary:** Monogram Technologies Inc. (MGRM) reported a net loss of $3.2 million for Q1 2025, showing slight improvements in operating expenses and cash flow compared to Q1 2024. The company secured FDA clearance for its mBôs™ TKA System, positioning it for market entry. However, it faces uncertainties related to geopolitical risks, potential litigation, and regulatory challenges. The company plans to continue raising capital and advancing its commercialization efforts while navigating these risks.